China’s CAR T market is expected to grow from $72 million in 2022 to $342 million over the next decade. There are currently more than 400 CAR T therapies in the pipeline in China, and most of these are being developed by specialized Chinese biotechs. Research by Clarivate plc, BioWorld’s parent company, indicates that a notable proportion of CAR T-cell therapies in late-phase development in China are being developed through strategic partnerships and joint ventures between multinational corporations and domestic companies, including Johnson & Johnson and Nanjing Legend Biotech Corp., Juno Therapeutics Inc. and Wuxi Apptec Co. Ltd., and CASI Pharmaceuticals Inc. and Juventas Cell Therapy Ltd.
The decision is another win for the Biden administration in a bitter legal fight with several drugmakers over the constitutionality of the price talks.
Two hundred Omicron cases reported in India so far, 5,326 new COVID-19 cases : Rashtra News #Omicron #cases #reported #India #COVID19 #cases Two hundred cases of Omicron variant of coronavirus have been detected in India so far out of which 77 patients have recovered or migrated, the Union Health Ministry said on December 21. Maharashtra